Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

Inclusion Criteria: * Subject has provided informed consent prior to initiation of any study-specific activities/procedures OR subject's legally acceptable representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent * Age greater than or equal to 18 years * B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) with minimal/measurable residual disease defined as hematologic complete remission (CR) with less than 5% bone marrow blasts and meets clinical eligibility criteria to receive blinatumomab as outlined below. * Hematologic criteria for remission as defined below: * Less than 5% bone marrow blasts * Absolute neutrophil count greater than or equal to 1.0 x10\^9 L * Platelets greater than or equal to 50 x10\^9/L (transfusion permitted) * Hemoglobin level greater than or equal to 90 g/L (transfusion permitted) * Renal and hepatic function as defined below: * Total bilirubin \<3 x upper limit of normal (ULN) unless related to Gilbert's or Meulengracht disease * Serum creatinine \<1.5 x ULN. If serum creatinine ≥1.5 x ULN, then measure Glomerular Filtration Rate (GFR); subject will be eligible only if measured GFR is within normal limits. * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 * Negative pregnancy test in women of child…